Examining the technical parameters, Amrutanjan Health Care’s trend has transitioned from mildly bullish to sideways, signalling a period of consolidation. Weekly MACD readings suggest a mildly bearish stance, while monthly MACD remains bullish, indicating mixed momentum signals. The Relative Strength Index (RSI) on both weekly and monthly charts shows no definitive signal, and Bollinger Bands reflect bearish tendencies on weekly and monthly timeframes. Daily moving averages maintain a mildly bullish posture, but the KST indicator on weekly and monthly scales leans mildly bearish. Dow Theory and On-Balance Volume (OBV) indicators reveal no clear trend, underscoring the technical ambiguity surrounding the stock.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- Precise target price set
- Weekly selection live
- Position check opportunity
From a valuation perspective, Amrutanjan Health Care is trading at a price to book value of 6, which aligns with its peers’ historical averages, suggesting a fair valuation in the current market context. The company’s Price/Earnings to Growth (PEG) ratio stands at 1.9, reflecting the relationship between its price-to-earnings ratio and earnings growth rate. Over the past year, the stock has generated a return of 0.66%, while profits have risen by 19.3%, indicating a moderate correlation between earnings growth and stock price movement. However, long-term growth metrics reveal a more tempered picture, with net sales expanding at an annual rate of 10.85% and operating profit growing at 2.59% over the last five years, pointing to restrained expansion in core business operations.
Financial trends for Amrutanjan Health Care show positive quarterly performance in Q2 FY25-26, supported by strong management efficiency. The company reports a return on equity (ROE) of 18.42%, highlighting effective utilisation of shareholder funds. Operating cash flow for the year reached Rs 50.90 crores, the highest recorded, while profit after tax (PAT) for the latest six months stood at Rs 22.27 crores, reflecting a growth rate of 35.63%. Return on capital employed (ROCE) for the half-year period is at 22.54%, underscoring robust capital efficiency. The company maintains a low average debt-to-equity ratio of zero, indicating minimal leverage and a conservative capital structure.
Considering Amrutanjan Health Care ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- Better options discovered
- Pharmaceuticals & Biotechnology + beyond scope
- Top-rated alternatives ready
Quality indicators for Amrutanjan Health Care reflect a mixed scenario. The company’s management efficiency is notable, with a high ROE of 18.42%, signalling effective operational control and profitability. However, institutional investor participation has declined, with a reduction of 1.34% in their stake over the previous quarter, now collectively holding 15.29% of the company. This decrease may suggest a cautious stance from investors with advanced analytical capabilities, potentially influenced by the stock’s subdued returns relative to the broader market. Over the last decade, the stock has delivered a return of 188.63%, trailing the Sensex’s 232.28% gain, while five-year returns of 42.16% also lag behind the Sensex’s 91.65%, highlighting a performance gap against benchmark indices.
On the price front, Amrutanjan Health Care’s current price stands at ₹708.15, marginally below the previous close of ₹710.40. The stock’s 52-week high is ₹829.00, with a low of ₹548.05, indicating a trading range that has seen moderate volatility. Daily price movements today ranged between ₹706.10 and ₹710.00, reflecting limited intraday fluctuation. Short-term returns have been negative, with a one-week return of -1.91% and a one-month return of -1.54%, contrasting with the Sensex’s positive returns of 0.96% and 0.86% respectively over the same periods. Year-to-date, the stock has declined by 2.47%, while the Sensex has advanced by 8.36%, underscoring relative underperformance in the current calendar year.
In summary, the adjustment in Amrutanjan Health Care’s evaluation is driven primarily by a shift in technical trends from mildly bullish to sideways, combined with a valuation that remains in line with sector peers but tempered by modest long-term growth rates. Financial metrics reveal strong management efficiency and capital returns, yet institutional investor interest has waned, reflecting a cautious market stance. Investors analysing this stock should consider the balance of these factors alongside broader market conditions and sector dynamics.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
